Casado, Pedro http://orcid.org/0000-0002-4207-9349
Rio-Machin, Ana http://orcid.org/0000-0001-6733-9752
Miettinen, Juho J. http://orcid.org/0000-0002-3987-1693
Bewicke-Copley, Findlay
Rouault-Pierre, Kevin
Krizsan, Szilvia http://orcid.org/0000-0002-1782-9275
Parsons, Alun
Rajeeve, Vinothini
Miraki-Moud, Farideh
Taussig, David C.
Bödör, Csaba
Gribben, John
Heckman, Caroline http://orcid.org/0000-0002-4324-8706
Fitzgibbon, Jude
Cutillas, Pedro R. http://orcid.org/0000-0002-3426-2274
Funding for this research was provided by:
Cancer Research UK (C15966/A24375, C15966/A24375, C15966/A24375, C15966/A24375, C15966/A24375, C15966/A24375, C15966/A24375)
Article History
Received: 20 May 2022
Revised: 18 November 2022
Accepted: 3 December 2022
First Online: 27 February 2023
Competing interests
: P.R.C. is cofounder and director of Kinomica Ltd. C.H. has received funding from BMS/Celgene, Kronos Bio, Novartis, Oncopeptides, Orion Pharma, and the IMI2 projects HARMONY and HARMONY PLUS. All other authors declare that they have no competing interests.